Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

21. Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone

Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone 27418597 2016 08 23 2017 05 15 2017 05 15 1524-4628 47 9 2016 Sep Stroke Stroke Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. 2323-30 10.1161/STROKEAHA.115.012293 In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent (...) recurrent cerebral ischemia. However, there is no clear evidence. In this multicenter, double-blind, placebo-controlled trial, we randomized 358 patients with acute ischemic stroke of presumed large artery atherosclerosis origin within 48 hours of onset to clopidogrel (75 mg/d without loading dose) plus aspirin (300-mg loading followed by 100 mg/d) or to aspirin alone (300-mg loading followed by 100 mg/d) for 30 days. The primary outcome was new symptomatic or asymptomatic ischemic lesion

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

22. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack. IMPORTANCE: Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated with clopidogrel. OBJECTIVE: To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients (...) with minor stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS: Three CYP2C19 major alleles (*2, *3, *17) were genotyped among 2933 Chinese patients from 73 sites who were enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted from January 2, 2010, to March 20, 2012. INTERVENTIONS: Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel

JAMA2016 Full Text: Link to full Text with Trip Pro

23. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome

Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome 26637834 2016 01 22 2017 01 09 2017 01 25 1522-9645 37 4 2016 Jan 21 European heart journal Eur. Heart J. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. 412-22 10.1093 (...) /eurheartj/ehv611 Studies have suggested increased cancer incidence associated with long-term dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS). We evaluated cancer incidence and treatment-related differences in an analysis of DAPT for ACS. The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel. Median treatment exposure was 15 months

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

24. Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis

Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis 28356861 2018 11 13 1452-8258 35 1 2016 Jan Journal of medical biochemistry J Med Biochem Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis. 26-33 10.1515/jomb-2015-0009 Despite the proven clinical effect of oral antiplatelet drugs, a considerable number of patients do not have (...) an adequate response to clopidogrel. The aim of our study was to determine the influence of CYP2C19*2 loss-of-function variant allele on clopidogrel responsiveness in patients with carotid artery stenosis. One hundred and twelve patients with carotid artery stenosis undergoing endarterectomy were included in this one-year prospective study. All of them received clopidogrel (75 mg daily) for at least 30 days after the intervention. They were followed from the moment of hospital admission. CYP2C19*2

Journal of medical biochemistry2015 Full Text: Link to full Text with Trip Pro

25. Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial.

Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial. 26551304 2015 11 25 2015 12 01 2016 10 17 1538-3598 314 20 2015 Nov 24 JAMA JAMA Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure: The CANOA Randomized Clinical Trial. 2147-54 10.1001/jama.2015.13919 The occurrence of new-onset migraine attacks is a complication (...) of transcatheter atrial septal defect (ASD) closure. It has been suggested that clopidogrel may reduce migraine attacks after ASD closure. To assess the efficacy of clopidogrel, used in addition to taking aspirin, for the prevention of migraine attacks following ASD closure. Randomized, double-blind clinical trial performed in 6 university hospitals in Canada. Participants were 171 patients with an indication for ASD closure and no history of migraine. Patients were randomized (1:1) to receive dual

JAMA2015 Full Text: Link to full Text with Trip Pro

26. Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy

Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy 26283758 2015 08 18 2015 11 03 2016 12 15 1526-632X 85 7 2015 Aug 18 Neurology Neurology Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. 573-9 10.1212/WNL.0000000000001844 We compared the effect of clopidogrel plus aspirin vs aspirin alone on functional outcome and quality of life in the Clopidogrel in High-risk Patients with Acute Non-disabling (...) Cerebrovascular Events (CHANCE) trial of aspirin-clopidogrel vs aspirin alone after acute minor stroke or TIA. Participants were assessed at 90 days for functional outcome using the modified Rankin Scale (mRS) and quality of life using the EuroQol-5 Dimension (EQ-5D). Poor functional outcome was defined as mRS score of 2-6 at 90 days and poor quality of life as EQ-5D index score of 0.5 or less. Poor functional outcome occurred in 254 patients (9.9%) in the clopidogrel-aspirin group, as compared with 299 (11.6

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

28. Rivaroxaban (Xarelto) - co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarker

Rivaroxaban (Xarelto) - co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarker

Scottish Medicines Consortium2015

29. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes

Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes 25957224 2015 07 07 2015 09 16 2015 07 07 1524-4539 132 1 2015 Jul 07 Circulation Circulation Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. 40-6 10.1161/CIRCULATIONAHA.114.014791 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment (...) of clopidogrel and aspirin decreases the 90-day risk of stroke without increasing hemorrhage in comparison with aspirin alone, but provided insufficient data to establish whether the benefit persisted over a longer period of time beyond the trial termination. We report the 1-year follow-up outcomes of this trial. The trial was a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China. We randomly assigned 5170 patients within 24 hours after onset of minor stroke or high-risk

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

30. Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland

Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland 25794517 2015 05 13 2015 07 20 2015 11 19 1468-201X 101 11 2015 Jun Heart (British Cardiac Society) Heart Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. 854-63 10.1136/heartjnl-2014-306925 To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (...) (ACS). Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines. Patients with ST-elevation myocardial infarction (STEMI) preferentially received prasugrel, while those with non-STEMI, a history of stroke or transient ischaemic attack, age ≥75 years, or weight <60 kg received clopidogrel or reduced dose of prasugrel to comply

EvidenceUpdates2015

32. Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines

Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions There appears to be uncertainty regarding the effectiveness of use

Health Technology Assessment (HTA) Database.2014

34. Clopidogrel/Acetylsalicylic acid Teva

Clopidogrel/Acetylsalicylic acid Teva 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 26 June 2014 EMA/CHMP/333195/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Clopidogrel / Acetylsalicylic (...) acid Teva International non-proprietary name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/002272/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised Assessment report EMA/502333/2014 Page 2/43 Table of contents 1. Background information on the procedure 6 2. Scientific discussion 8 2.1. Quality aspects 8 2.2. Non-clinical aspects 13 2.3. Clinical aspects 19 2.4. Clinical efficacy 28

European Medicines Agency - EPARs2014

35. Clopidogrel Qualimed

Clopidogrel Qualimed European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged. Doc. Ref.:EMEA/506895/2009 CHMP ASSESSMENT REPORT FOR Clopidogrel Qualimed International Nonproprietary Name: clopidogrel Procedure No. EMEA/H/C/001135 Assessment Report as adopted by the CHMP (...) no longer authorised 1. BACKGROUND INFORMATION ON THE PROCEDURE 1.1 Submission of the dossier Qualimed submitted on 20 February 2009 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Clopidogrel Qualimed , in accordance with the centralised procedure falling within the scope of the Annex to Regulation (EC) 726/2004 under Article 3 (3) – ‘Generic of a Centrally authorised product’. The legal basis for this application refers to Article 10(1) of Directive 2001/83/EC

European Medicines Agency - EPARs2014

36. Clopidogrel in infants with systemic-to-pulmonary-artery shunts

Clopidogrel in infants with systemic-to-pulmonary-artery shunts PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2013

37. Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do?

Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? Samie AA, Theilmann L CRD summary This review concluded that data on bleeding risk of endoscopic procedures in patients under clopidogrel/antiplatelet therapy were scarce and poor quality (...) , but that there was no evidence to support the recommendations to stop clopidogrel prior to high-risk endoscopic procedures. The potential for missed studies, lack of quality assessment and inappropriate synthesis mean these conclusions may not be reliable. Authors' objectives To determine the bleeding risk with gastrointestinal endoscopic procedures performed in patients under clopidogrel/dual antiplatelet therapy. Searching MEDLINE, EMBASE and The Cochrane Library were searched for English language studies up to October

DARE.2013

39. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. BACKGROUND: Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only (...) . We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen. METHODS: TRILOGY ACS (ClinicalTrials.gov number NCT00699998 ) was a randomised controlled trial, done at more than 800 sites worldwide. Patients with non-ST-elevation acute coronary syndrome who were selected for management without [corrected] revascularisation were randomly assigned to clopidogrel or prasugrel.The primary endpoint was cardiovascular death

Lancet2013

40. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. BACKGROUND: Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. METHODS: In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset (...) of minor ischemic stroke or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat

NEJM2013